Compounds > pyrroles
Page last updated: 2024-08-18

pyrroles and Hyperlipoproteinemia Type III

pyrroles has been researched along with Hyperlipoproteinemia Type III in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bari, AU; Hashim, R; Hussain, M; Rahman, SB1
Cho, EJ; Kim, CJ; Kim, JE; Kwon, JE; Min, YJ; Oh, MS1
Inazu, A; Kawashiri, MA; Kobayashi, J; Mabuchi, H; Nakanishi, C; Noguchi, T; Nohara, A; Tada, H; Yamagishi, M1
de Beer, F; Havekes, LM; Kastelein, JJ; Lansberg, PJ; Prins, MH; Smelt, AH; Trip, MD; van Dam, M; Zwart, M1
Hirano, K; Hiraoka, H; Ishigami, M; Matsuzawa, Y; Nakamura, T; Sakai, N; Yamashita, S1
Arishima, H; Katafuchi, R; Matsunaga, A; Rye, KA; Saku, K; Zhang, B1

Trials

1 trial(s) available for pyrroles and Hyperlipoproteinemia Type III

ArticleYear
Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.
    Clinica chimica acta; international journal of clinical chemistry, 2011, May-12, Volume: 412, Issue:11-12

    Topics: Aged; Apolipoprotein E2; Apolipoprotein E3; Atorvastatin; Bezafibrate; Chromatography, High Pressure Liquid; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Phenotype; Pyrroles

2011

Other Studies

5 other study(ies) available for pyrroles and Hyperlipoproteinemia Type III

ArticleYear
Familial dysbetalipoproteinemia: a potentially fatal disorder.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2008, Volume: 18, Issue:8

    Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Male; Pyrroles; Risk Factors

2008
Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia.
    The American journal of cardiology, 2011, Mar-01, Volume: 107, Issue:5

    Topics: Angina Pectoris; Atorvastatin; Drug Therapy, Combination; Electrocardiography; Exercise Test; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Middle Aged; Pyrroles; Tomography, X-Ray Computed

2011
Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia.
    Heart (British Cardiac Society), 2002, Volume: 88, Issue:3

    Topics: Adult; Aged; Apolipoproteins B; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type III; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides

2002
Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins.
    Atherosclerosis, 2003, Volume: 168, Issue:2

    Topics: Aged; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins; Apolipoproteins B; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hyperlipoproteinemia Type III; Lipids; Lipoproteins; Male; Middle Aged; Osmolar Concentration; Pyrroles; Triglycerides

2003
Effects of atorvastatin and apoA-I/phosphatidylcholine discs on triglyceride-rich lipoprotein subfractions as characterized by capillary isotachophoresis.
    Clinica chimica acta; international journal of clinical chemistry, 2006, Volume: 373, Issue:1-2

    Topics: Adult; Apolipoprotein A-I; Apolipoprotein E2; Atorvastatin; Electrophoresis, Capillary; Heptanoic Acids; Humans; Hyperlipoproteinemia Type III; Lipoproteins; Macromolecular Substances; Male; Phenotype; Phosphatidylcholines; Pyrroles; Sensitivity and Specificity; Time Factors; Triglycerides

2006